Cheyney, PA – According to filings with the U.S. Securities and Exchange Commission, Navrogen is raising $7,956,662.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Nicholas Nicolaides played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Navrogen
Navrogen Inc. is a biopharmaceutical company focused on the targeted treatment of cancer. Navrogen is currently working on enhancing the immune system to fight cancer by removing the effect of factors produced or induced by tumor cells which inhibit the cancer-fighting humoral immune system.

To learn more about Navrogen, visit http://navrogen.com/

Contact:
Nicholas Nicolaides, Chief Executive Officer
610-399-2717
nick@navrogen.com
https://www.linkedin.com/in/nicholas-nicolaides-435a4126/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved